Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K0YC
|
|||
| Former ID |
DCL000363
|
|||
| Drug Name |
PD-0325901
|
|||
| Synonyms |
PD 0325901; PD 325901; PD0325901; PD325901; PD-325901; S06-0029; N-[((R)-2,3-dihydroxypropyl)oxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide; N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodo-phenyl)amino]benzamide; N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50] | Phase 2 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H14F3IN2O4
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1I)F)NC2=C(C=CC(=C2F)F)C(=O)NOCC(CO)O
|
|||
| InChI |
1S/C16H14F3IN2O4/c17-11-3-2-10(16(25)22-26-7-9(24)6-23)15(14(11)19)21-13-4-1-8(20)5-12(13)18/h1-5,9,21,23-24H,6-7H2,(H,22,25)/t9-/m1/s1
|
|||
| InChIKey |
SUDAHWBOROXANE-SECBINFHSA-N
|
|||
| CAS Number |
CAS 391210-10-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
14785709, 24128853, 44924660, 57269492, 57288454, 71825013, 76715719, 79870585, 85752745, 85786733, 99376100, 99436950, 99443572, 103589409, 123051120, 124391899, 124756951, 124899408, 125088141, 125163757, 126578301, 126666970, 126671480, 126735952, 131465114, 131488510, 134339013, 135268452, 135317694, 135602519, 135697659, 135707789, 135727388, 136367839, 136380061, 136895331, 136920361, 137242802, 139159470, 143496680, 144116344, 144206915, 151994937, 152234952, 152258155, 152344237, 160646992, 160814718, 160968186, 162011411
|
|||
| ChEBI ID |
CHEBI:88249
|
|||
| Drug Resistance Mutation (DRM) | Top | |||
|---|---|---|---|---|
| DRM | DRM Info | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7935). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020671) | |||
| REF 3 | MEK and the inhibitors: from bench to bedside. J Hematol Oncol. 2013; 6: 27. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.